Analyst Price Targets — PFE
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| March 17, 2026 12:39 pm | Terence Flynn | Morgan Stanley | $27.00 | $27.06 | StreetInsider | Morgan Stanley on Pfizer (PFE): Atirmo Ph2 data an 'incremental positive' |
| March 9, 2026 3:51 pm | Evan David Seigerman | BMO Capital | $30.00 | $26.49 | StreetInsider | BMO Capital Reiterates Outperform Rating on Pfizer (PFE) following Ph2 data |
| February 24, 2026 9:05 pm | Trung Huynh | RBC Capital | $25.00 | $27.14 | StreetInsider | RBC Capital Starts Pfizer (PFE) at Underperform |
| February 19, 2026 9:17 pm | Emily Field | Barclays | $25.00 | $26.86 | TheFly | Pfizer initiated with an Underweight at Barclays |
| February 12, 2026 10:10 am | Narumi Nakagiri | Daiwa | $27.00 | $27.73 | TheFly | Pfizer downgraded to Neutral from Outperform at Daiwa |
| January 27, 2026 12:21 pm | — | Cantor Fitzgerald | $27.00 | $25.88 | TheFly | Pfizer price target raised to $27 from $24 at Cantor Fitzgerald |
| January 6, 2026 10:06 pm | — | UBS | $25.00 | $25.43 | TheFly | Pfizer assumed with a Neutral at UBS |
| December 17, 2025 9:24 am | Alexandria Hammond | Wolfe Research | $24.00 | $25.53 | StreetInsider | Pfizer (PFE) PT Lowered to $24 at Wolfe Research |
| December 12, 2025 1:12 pm | — | Morgan Stanley | $28.00 | $25.89 | TheFly | Pfizer price target lowered to $28 from $32 at Morgan Stanley |
| December 10, 2025 11:17 am | Rajesh Kumar | HSBC | $29.00 | $25.33 | TheFly | Pfizer price target raised to $29 from $28 at HSBC |
Latest News for PFE
Pfizer Inc. (PFE) currently receives a buy rating from Wall Street, but I believe the rating is overoptimistic. Political uncertainties around 'TrumpRx' and 'Most-Favored-Nation' drug pricing models continue to threaten PFE's margins and valuation outlook. PFE's FWD P/E of 9.3x appears attractive on the surface, but is actually not once the multi-year earnings decline risks are factored in.
Pfizer started 2026 on a high note despite ongoing skepticism from retail investors. Its key anti-cancer drugs, Padcev, Lorbrena, and Talzenna, showed strong performance in Q4. Accordingly, sales of Talzenna rose 81.5% year-on-year to $49 million.
In the closing of the recent trading day, Pfizer (PFE) stood at $27.57, denoting a +1.06% move from the preceding trading day.
Pfizer (NYSE: PFE) is one of the most widely held dividend stocks among retirement investors.
First Bank and Trust lifted its stake in shares of Pfizer Inc. (NYSE: PFE) by 21.5% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 184,140 shares of the biopharmaceutical company's stock after acquiring an additional 32,523 shares during the quarter. Pfizer
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
Senate Trading Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
U.S. House Trading
House Trades Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.